Feyi Olopade Ayodele: CancerIQ Eases Access to Genetic Screening in Community Cancer Centers

CancerIQ has automated a lot of time-consuming steps to allow operationally efficient community cancer centers a way of offering genetic screening in a profitable manner, said Feyi Olopade Ayodele, MBA, chief executive officer at CancerIQ.

Transcript

How does CancerIQ break down some of the barriers facing community oncologists who want to offer genetic services to patients?

CancerIQ is really trying to break down several of the barriers for community oncologists by doing 2 things. One is making it so that they can incorporate it into their workflow without additional time. Unfortunately, a lot of genetics providers today are spending time manually collecting family history information, writing long love letters to insurance companies, and spending more time on clinical documentation than they are on patient care. With CancerIQ, we’ve really automated a lot of these steps that do take a lot of time and made it so that an operationally efficient community cancer center has a way of doing this in a profitable manner.

I think the second thing that we’re doing is we really are huge on education and making sure that everything our providers are doing is clinically relevant and evidence-based. We have a partnership, the NCCN, to integrate their clinical guidelines into CancerIQ so that every provider has this knowledge at their fingertips. We’re also working with different patient advocacy organizations to make sure that patient-facing content and that support that’s needed in the community cancer centers can be delivered to those patients in a scalable manner.